Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to see if Lung LLC's new experimental formulation of the medicine Beraprost Sodium, called Beraprost Sodium 314d Modified Release (BPS-314d-MR), can improve the symptoms of pulmonary arterial…
- Trial name
- NCT01966302
- Testing
- BPS-314d-MR
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Pulmonary Arterial Hypertension
Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension
Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.
- Trial name
- NCT04808830
- Testing
- Evaluation of musculoskeletal pain prevalence, Evaluation of quality of life, Evaluation of functional exercise capacity
- Where
- Turkey (Türkiye)
- Volunteers
- 61 people
- Sponsor
- Izmir Bakircay University
Pulmonary Arterial Hypertension
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers.
- Trial name
- DELPHI-2 (NCT01600898)
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Hypertension, Sickle Cell Disease
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects.
- Trial name
- MENSCH (NCT02651272)
- Testing
- macitentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Hypertension, Pulmonary
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real…
- Trial name
- VENTASTEP (NCT03293407)
- Testing
- Iloprost (Ventavis, BAYQ6256), Breelib nebulizer
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
ACT-293987 in Pulmonary Arterial Hypertension
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
- Trial name
- NCT01112306
- Testing
- ACT-293987
- Where
- 157 sites in United States, Argentina and 36 more
- Volunteers
- 709 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular affection, which treatment has evolved in the last few years, improving quality of life. However, adherence to treatment has not been assessed in such patients.
- Trial name
- ETHAP (NCT01038284)
- Testing
- Patient education, Data collection
- Where
- 11 sites in France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Idiopathic Arterial Hypertension
Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair. Current evidence established that endothelial progenitor cells (EPC) participate in several models of…
- Trial name
- NCT00551408
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Unidad de Investigacion Clinica en Medicina S.C.
Hypertension, Pulmonary
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
The purpose of this study is to determine whether aspirin and simvastatin are safe and effective for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00384865
- Testing
- Simvastatin, Aspirin
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Pennsylvania
Pulmonary Hypertension, Pulmonary Arterial Hypertension
The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension
The aim of this study is to 1) descriptively report possible in flight events and 2) to provide regression analysis if the number of events are statistically significant in their prevalence and thus are useful in finding possible…
- Trial name
- PEGASUS (NCT03051763)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Giessen
Schistosomiasis
Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension is a progressive and potentially fatal cardiopulmonary disorder characterized by remodeling of the pulmonary vasculature, progressive elevation of pulmonary vascular resistance (PVR), and eventual…
- Trial name
- Sch-PAH RV-PA (NCT07707193)
- Testing
- right heart catheterization for measure pulmonary artery pressure
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe clinical conditions that, despite advances in therapeutics over the past 20 years, lead to serious morbidity and…
- Trial name
- NCT05618093
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles
Chronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Determinants of Right Heart Remodeling in Patients With CTEPH or PAH
Right heart failure is the main cause of morbi-mortality in patients with pulmonary hypertension (PH), including patients of chronic thrombo-embolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)…
- Trial name
- PRINCEPT (NCT03205085)
- Testing
- magnetic resonance imaging, 2D and 3D trans-thoracic echocardiography, Blood samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Ventricular Function
- Trial name
- MIRROR-PAH (NCT07667673)
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Idiopathic Pulmonary Arterial Hypertension
Iron Deficiency In Pulmonary Hypertension
Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiency were previously shown to have a decreased six-minute walking distance.
- Trial name
- NCT01288651
- Testing
- Ferricarboxymaltose
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)
Characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
- Trial name
- PreVailPH2 OUS (NCT06495970)
- Testing
- Gradient Denervation System
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Gradient Denervation Technologies
Intrahepatic Cholangiocarcinoma (Icc)
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor…
- Trial name
- NCT07304388
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Pulmonary Arterial Hypertension
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures.
- Trial name
- NCT05439460
- Testing
- Phenylephrine, Epinephrine, Arginine Vasopressin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Pulmonary Hypertension, Precapillary Pulmonary Hypertension
Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
The goal of this observational study is to validate digital mobility outcomes for monitoring the treatment and disease progression in adult patients with pulmonary hypertension.
- Conditions
- Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, Digital Mobility Outcomes
- Trial name
- NCT07137260
- Testing
- Accelerometer (measurement of walking activity)
- Where
- 4 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Simon Jäger
Pulmonary Arterial Hypertension
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
This prospective, non-interventional, multi-center study documents observational data on subjects under routine treatment of Pulmonary Arterial Hypertension, functional class III with inhaled Iloprost administered with I-Neb AAD…
- Trial name
- DAILY (NCT01781052)
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Bayer